Cardio Diagnostics Holdings Advances AI-Powered Cardiovascular Testing with Expanded Access and CMS Reimbursement

Cardio Diagnostics Holdings (NASDAQ: CDIO) represents a significant advancement in cardiovascular medicine through its artificial intelligence-powered precision approach. The company focuses on making cardiovascular disease prevention, detection, and management more accessible, personalized, and precise by moving beyond traditional methods that rely on indirect or generalized indicators. Cardiovascular disease remains the leading cause of death in the United States, representing a substantial healthcare burden that the company's solutions aim to address.

The proprietary platform developed by Cardio Diagnostics integrates epigenetic and genetic biomarkers with artificial intelligence to generate personalized cardiovascular insights from a simple blood sample. This approach analyzes both inherited predisposition and changes influenced by lifestyle and environment to provide a more comprehensive assessment of cardiovascular health. The company's clinical tests are non-invasive, require no fasting or radiation, and are designed to detect and assess coronary heart disease, including forms that may not be identified through traditional diagnostic methods.

Recent developments highlight the growing adoption and validation of Cardio Diagnostics' approach. The company has expanded provider partnerships across the United States and finalized Centers for Medicare & Medicaid Services reimbursement rates of $854 for its clinical tests. This reimbursement represents a critical milestone for broader patient access and insurance coverage. Additionally, the company has initiated international expansion into India, demonstrating the global potential of its technology. Clinical data presentations have supported the platform's ability to detect forms of coronary heart disease that traditional diagnostic tools may miss.

The company has established multiple commercialization channels to expand access to its cardiovascular testing solutions, including provider networks, employer partnerships, and community-based programs. These channels are designed to make the technology available to diverse patient populations. The core strategy integrates epigenetics, genetics, and artificial intelligence to generate insights from a patient's molecular profile, potentially transforming how cardiovascular disease is addressed in clinical practice.

Forward-looking statements in the company's communications acknowledge risks and uncertainties, as detailed in SEC filings available through the company's newsroom at https://ibn.fm/CDIO. These statements are subject to various factors beyond management's control, and undue reliance should not be placed on them when making investment decisions. The full terms of use and disclaimers applicable to all content are available on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.